Dabrafenib/Trametinib Combo Provides Lasting Control for BRAF V600-Mutant Metastatic Melanoma

Published: Thursday, Jun 06, 2019
Five years out, one-third of patients with unresectable or metastatic BRAF V600-mutant melanoma remained alive following treatment with dual targeted therapy with dabrafenib (Tafinlar) plus trametinib (Mekinist), and 1 in 5 remained alive without progression, according to an analysis COMBI-d and COMBI-v trials reported at the 2019 ASCO Annual Meeting.1

 

References

  1. Nathan P, Robert C, Grob JJ, et al. Five-year analysis of dabrafenib plus trametinib in patients with BRAF V600-mutant unresectable or metastatic melanoma. J Clin Oncol. 2019;37 (suppl; abstr 9507).
  2. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK Inhibition versus BRAF inhibition alone in melanoma. N Eng J Med. 2014; 371:1877-1888 doi: 10.1056/NEJMoa1406037.
  3. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30-39. doi: 10.1056/NEJMoa1412690.
  4. Schadendorf D, Long GV, Strojakovski D, et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer. 2017;82:45-55.
<<< 2019 ASCO Annual Meeting
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x